Sector News

With big debt on tap, analysts see Takeda-Shire deal as 'more likely than not'

April 6, 2018
Life sciences

After Takeda revealed last week that it was eyeing a Shire buy, industry watchers expressed skepticism that the company could pull it off. Now, though, some analysts like the Japanese drugmaker’s chances.

In a Thursday meeting, Takeda told analysts it was “willing to push its debt higher” in order to seal the deal, Bernstein’s Wimal Kapadia wrote to clients. And in light of that fact, he now sees a potential transaction as “more likely than not.”

“We think the deal is likely because there is willing buyer, willing sellers and room to meet both sides’ expectations,” he wrote.

Shire shares have been struggling hard; new hemophilia competition from Roche has prevented them from bouncing back after a less-than-stellar Baxalta buy that left the company “too levered to do anything itself” as far as M&A goes.

But while “Shire stand-alone struggles with negative earnings revisions and lack of catalysts in the near-term,” Takeda can afford to wait for the tide to turn. “The objective for Takeda is 2025 positioning,” Kapadia pointed out.

Of course, just because Shire shareholders are open to a sale doesn’t mean there’s overlap between the price they want and what Takeda’s willing to lay down, he noted. According to a Bernstein survey, investors are hoping for £42/$175 per share to kick off negotiations and £45/$190 to ink an agreement—as well as less than 50% in Takeda shares.

Other analysts had previously voiced doubts that Takeda could afford a Shire buy after its interest announcement sank shares but sent Shire’s soaring.

But the way Kapadia sees things, Takeda can probably get it done thanks to a willingness to go to 5x leverage and the opportunity to issue shares locally, which would reduce the shares issued to Shire investors.

“We believe the local market will be willing to absorb more Takeda stock given the positive local headlines and limited share movement down since the deal has been announced,” Kapadia wrote.

Meanwhile, the pharma intends to drum up some extra cash with a sale of its Brazil-based pharma unit, Multilab Indústria e Comércio de Produtos Farmacêuticos, Reuters reported. Takeda plans to offload the business to Novamed Fabricação de Produtos Farmacêuticos in June at an undisclosed price.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

March 19, 2023

Ferring Pharmaceuticals’ 1st in class C.diff Treatment, Rebyota, experiences a positive early launch ahead of potential competition

Life sciences

With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.

March 19, 2023

UCB enters drug discovery collaboration with Aitia

Life sciences

Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.

March 19, 2023

Novo, Medtronic add $25M in fuel to FIRE1 and its heart failure monitoring device

Life sciences

Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.

How can we help you?

We're easy to reach